Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BrightGene

- PMLiVE

EMA recommends new manufacturing sites for COVID-19 vaccines

EMA also recommends new storage temperature for Pfizer/BioNTech vaccine

- PMLiVE

Single Pfizer/BioNTech dose induces strong immune response to COVID-19

Study finds 99% of people generated a robust immune response against COVID-19 after single vaccine dose

- PMLiVE

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

FDA approved the antibody-drug conjugate in this indication in April 2020

- PMLiVE

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.

Avalere Health

- PMLiVE

EU leaders debate COVID-19 vaccine export measures during virtual summit

AstraZeneca urged to ‘honour’ contract with EU before exporting doses elsewhere

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

Wearable Technologies for Detecting Pre-Symptomatic Illness and Infections

Dr. Tejaswini Mishra, Research Scientist at Stanford University School of Medicine, dives into her research on using wearable technologies for detecting COVID-19 and other diseases before patients become symptomatic. Among...

Impetus Digital

- PMLiVE

UK plans to launch new national health agency focused on tackling pandemics

The UK Health Security Agency will protect against future health threats

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Pfizer launches early study of COVID-19 antiviral therapeutic

Therapeutic candidate has demonstrated 'potent' in vivo activity against SARS-CoV-2

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links